Prime Medicine Inc (NASDAQ: PRME) flaunted slowness of -10.54% at $3.99, before settling in for the price of $4.46 at the close. Taking a more long-term approach, PRME posted a 52-week range of $3.28-$9.86.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that the giant of the Healthcare sector posted annual sales growth of -25.00% over the last 5 years. Meanwhile, its Annual Earning per share during the time was -193.88%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 25.11%. This publicly-traded company’s shares outstanding now amounts to $97.38 million, simultaneously with a float of $39.57 million. The organization now has a market capitalization sitting at $478.92 million. At the time of writing, stock’s 50-day Moving Average stood at $3.93, while the 200-day Moving Average is $5.80.
Prime Medicine Inc (PRME) Ownership Facts and Figures
Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the Prime Medicine Inc industry. Prime Medicine Inc’s current insider ownership accounts for 67.03%, in contrast to 36.60% institutional ownership. According to the most recent insider trade that took place on Feb 15 ’24, this organization’s Director bought 3,200,000 shares at the rate of 6.25, making the entire transaction reach 20,000,000 in total value, affecting insider ownership by 3,200,000. Preceding that transaction, on Feb 15 ’24, Company’s 10% Owner bought 3,200,000 for 6.25, making the whole transaction’s value amount to 20,000,000. This particular insider is now the holder of 3,200,000 in total.
Prime Medicine Inc (PRME) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.45 per share during the current fiscal year.
Prime Medicine Inc’s EPS increase for this current 12-month fiscal period is 25.11% and is forecasted to reach -1.40 in the upcoming year.
Prime Medicine Inc (NASDAQ: PRME) Trading Performance Indicators
Let’s observe the current performance indicators for Prime Medicine Inc (PRME). It’s Quick Ratio in the last reported quarter now stands at 8.23. The Stock has managed to achieve an average true range (ATR) of 0.34. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 811.73.
In the same vein, PRME’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.13, a figure that is expected to reach -0.38 in the next quarter, and analysts are predicting that it will be -1.40 at the market close of one year from today.
Technical Analysis of Prime Medicine Inc (PRME)
Now, what If we examine the latest scores posted by [Prime Medicine Inc, PRME]. During the last 5-days, its volume was better the volume of 0.98 million it reported in year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 80.30% While, its Average True Range was 0.35.
Raw Stochastic average of Prime Medicine Inc (PRME) in the period of the previous 100 days is set at 14.60%, which indicates a major fall in contrast to 54.63% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 88.26% that was lower than 89.60% volatility it exhibited in the past 100-days period.
